Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1973

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

DMPA as an injectable contraceptive: good or bad?

AUTHORS

McDaniel EB

SOURCE

Journal of Christian Medical Association of India 48(3): 98-100. 1973.

ABSTRACT

Injectible medroxyprogesterone acetate (DMPA) is evaluated for its suitability as a contraceptive. The drug is

considered safe and effective with a failure rate higher than the pill but lower than the IUD. It is reasonably cheap

and is easy to use, requiring only a simple injection every 3 or 6 months. A safety period of several weeks overlaps

the next due date. The drug does not interfere with lactation. A disadvantage of the contraceptive is the side effects,

the most troublesome of which are bleeding problems, including irregular periods, amenorrhea, spotting, and (rarely)

heavy bleeding. Administration of an oral estrogen supplement may help to cut down on these side effects. Another

disadvantage of DMPA is a period of infertility after stopping treatment. Return of fertility during the 1st year after

discontinuation is somewhat lower than that seen after the use of orals or IUDs. However, 82.4% of 135 women who

discontinued for planned pregnancy became pregnant. It is concluded that 3-monthly or 6-monthly injections of

DMPA fulfill most of the criteria for a good, temporary contraceptive injection. (PubHealth.info Document ID: CONT8T

551-06)

PubHealth.info NOTE: The author(s) of this article titled, "DMPA as an injectable contraceptive: good or bad?",

is(are) McDaniel EB. The source of this article is "Journal of Christian Medical Association of India 48(3): 98-100.

1973.". This article was published in 1973 in English language(s). (PubHealth.info® Document ID: CONT8T 551-06.

All rights reserved with PubHealth.info) PIN: 35551

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.